Keywords: ra, golimumab, patients, see, das28, remissions, findings
RA golimumab patients see DAS28 remissions
Article | 23 June 2008
Findings from two new Phase III studies showed that patients receiving subcutaneous injections of Centocor's golimumab (CNTO 148) 50mg and 100mg ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
